Gut: A key player in the pathogenesis of type 2 diabetes?

References

• Adrian, T. E., Sagor, G. R., Savage, A. P., Bacarese-Hamilton, A. J., Hall, G. M. and Bloom, S. R. (1986). Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in man. J. Clin. Endocrinol Metab. 63(4):803–807.
   PubMed Web of Science ®Google Scholar
• Ahren, B. and Larsson, H.(1996). Peptide YY does not inhibit glucose-stimulated insulin secretion in humans. Eur. J. Endocrinol. 134(3):362–365.
   PubMed Web of Science ®Google Scholar
• Ahrén, B., Holst, J. J. and Efendic, S. (2000). Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J. Clin. Endocrinol. Metab. 85(3):1043–1048.
   PubMed Web of Science ®Google Scholar
• Althage, M. C., Ford, E. L., Wang, S., Tso, P., Polonsky, K. S., and Wice, B. M. (2008). Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J. Biol. Chem. 283(26):18365–18376.
   PubMed Web of Science ®Google Scholar
• Amini, P., Wadden, D., Cahill, F., Randell, E., Vasdev, S., Chen, X., Gulliver, W., Zhang, W., Zhang, H., Yi, Y. and Sun, G. (2012). Serum acylated ghrelin is negatively correlated with the insulin resistance in the CODING study. Plos One 7(9):e45657.
   PubMed Web of Science ®Google Scholar
• Anderwald, C., Brabant, G., Bernroider, E., Horn, R., Brehm, A., Waldhäusl, W. and Roden, M. (2003). Insulin-dependent modulation of plasma ghrelin and leptin concentrations is less pronounced in type 2 diabetic patients. Diabetes. 52(7):1792–1798.
   PubMed Web of Science ®Google Scholar
• Anini, Y. and Brubaker, P. L. (2003). Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes. 52(2):252–259.
   PubMed Web of Science ®Google Scholar
• Asmar, M., Tangaa, W., Madsbad, S., Hare, K., Astrup, A., Flint, A., Bülow, J. and Holst, J.J. (2010). On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. Am. J. Physiol. Endocrinol. Metab. 298(3):E614–E621.
   PubMed Web of Science ®Google Scholar
• Backhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F. and Gordon, J. I. (2004). The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. U S A. 101(44):15718–15723.
   PubMed Web of Science ®Google Scholar
• Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J. and Vilsboll, T. (2011). Impaired regulation of the incretin effect in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 96:737–745.
   PubMed Web of Science ®Google Scholar
• Bahrami, J., Longuet, C., Baggio, L. L., Li, K. and Drucker, D. J. (2010). Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. Gastroenterology, 96(3):737–745.
   Google Scholar
• Baldassano, S. and Amato, A. (2014). GLP-2: What do we know? What are we going to discover?. Regul. Peptides 194–195:6–10.
   PubMedGoogle Scholar
• Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S. and Bloom, S. R. (2003). Inhibition of food intake in obese subjects by peptide YY 3–36. New Engl. J. Med., 349(10):941–948.
   PubMed Web of Science ®Google Scholar
• Bennet, H., Balhuizen, A., Medina, A., Dekker Nitert, M., Ottosson Laakso, E., Essén, S., Spégel, P., Storm, P., Krus, U., Wierup, N. and Fex, M. (2015). Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes. Peptides. 71:113–120.
   PubMed Web of Science ®Google Scholar
• Boey, D., Lin, S., Karl, T., Baldock, P., Lee, N., Enriquez, R. and Herzog, H. (2006). Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia. 49(6):1360–1370.
   PubMed Web of Science ®Google Scholar
• Breen, D. M., Rasmussen, B. A., Côté, C. D., Jackson, V. M. and Lam, T. K. (2013). Nutrient-sensing mechanisms in the gut as therapeutic targets for diabetes. Diabetes. 62(9):3005–3013.
   PubMed Web of Science ®Google Scholar
• Broglio, F., Arvat, E., Benso, A., Gottero, C., Muccioli, G., Papotti, M., van der Lely, A. J., Deghenghi, R. and Ghigo, E. (2001). Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J. Clin. Endocrinol. Metab. 86(10):5083–5086.
   PubMed Web of Science ®Google Scholar
• Broglio, F., Prodam, F., Riganti, F., Gottero, C., Destefanis, S., Granata, R., Muccioli, G., Abribat, T., van der Lely, A. J. and Ghigo, E. (2008). The continuous infusion of acylated ghrelin enhances growth hormone secretion and worsens glucose metabolism in humans. J. Endocrinol. Invest. 31(9):788–794.
   PubMed Web of Science ®Google Scholar
• Broussard, J. L., Kilkus, J. M., Delebecque, F., Abraham, V., Day, A., Whitmore, H. R. and Tasali, E. (2016). Elevated ghrelin predicts food intake during experimental sleep restriction. Obesity (Silver Spring). 24(1):132–138.
   PubMed Web of Science ®Google Scholar
• Bulotta, A., Farilla, L., Hui, H. and Perfetti, R. (2004). The role of GLP-1 in the regulation of islet cell mass. Cell Biochem. Biophys. 40(3):65–78.
   PubMed Web of Science ®Google Scholar
• Burcelin, R., Serino, M., Chabo, C., Blasco-Baque, V. and Amar, J. (2011). Gut microbiota and diabetes: From pathogenesis to therapeutic perspective. Acta Diabetol. 48:257–273.
   PubMed Web of Science ®Google Scholar
• Camilleri, M., Papathanasopoulos, A. and Odunsi, S. T. (2009). Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat. Rev. Gastroenterol. Hepatol. 6(6):343–352.
   Web of Science ®Google Scholar
• Cani, P. D., Geurts, L., Matamoros, S., Plovier, H. and Duparc, T. (2014). Glucose metabolism: Focus on gut microbiota, the endocannabinoid system and beyond. Diab. Metab. 40(4):246–257.
   PubMed Web of Science ®Google Scholar
• Chia, C. W., Carlson, O. D., Kim, W., Shin, Y. K., Charles, C. P., Kim, H. S., Melvin, D. L. and Egan, J. M. (2009). Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes. 58(6):1342–1349.
   PubMed Web of Science ®Google Scholar
• Christensen, M., Calanna, S., Sparre-Ulrich, A. H., Kristensen, P. L., Rosenkilde, M. M., Faber, J., Purrello, F., Van Hall, G., Holst, J. J., Vilsbøll, T., Knop, F. K. (2015). Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Diabetes. 64(1):72–78.
   PubMed Web of Science ®Google Scholar
• Christensen, S. E., Hansen, A. P., Weeke, J. and Lundbaek, K. (1978). 24-hour studies of the effects of somatostatin on the levels of plasma growth hormone, glucagon, and glucose in normal subjects and juvenile diabetics. Diabetes. 27(3):300–306.
   PubMed Web of Science ®Google Scholar
• Cox, H. M., Tough, I. R., Woolston, A.-M., Zhang, L., Nguyen, A. D., Sainsbury, A. and Herzog, H. (2010). Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses. Cell Metabolism. 11(6):532–542.
   PubMed Web of Science ®Google Scholar
• Crockett, S. E., Mazzaferri, E. L. and Cataland, S. (1976).Gastric inhibitory polypeptide (GIP) in maturity-onset diabetes mellitus. Diabetes. 25(10):931–935.
   PubMed Web of Science ®Google Scholar
• Cummings, D. E., Overduin, J., Foster-Schubert, K. E. and Carlson, M. J. (2007). Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg. Obesity Relat Diseases. 3(2):109–115.
   PubMed Web of Science ®Google Scholar
• Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E. and Weigle, D. S. (2001). A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 50(8):1714–1749.
   PubMed Web of Science ®Google Scholar
• D'Alessio, D. A. and Ensinck, J. W. (1990). Fasting and postprandial concentrations of somatostatin-28 and somatostatin-14 in type II diabetes in men. Diabetes. 39(10):1198–1202.
   PubMed Web of Science ®Google Scholar
• Dash, S., Xiao, C., Morgantini, C., Connelly, P. W., Patterson, B. W. and Lewis, G. F. (2014). Glucagon-like peptide-2 regulates release of chylomicrons from the intestine. Gastroenterology. 147(6):1275–1284.e4.
   PubMed Web of Science ®Google Scholar
• De Heer, J., Pedersen, J., Orskov, C. and Holst, J. J. (2007). The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia. 50(10):2135–2142.
   PubMed Web of Science ®Google Scholar
• De Jonghe, B. C., Hajnal, A. and Covasa, M. (2005). Increased oral and decreased intestinal sensitivity to sucrose in obese, prediabetic CCK-A receptor-deficient OLETF rats. Am. J. Physiol. Regul. Integr. Comparat. Physiol. 288(1):R292–R300.
   PubMed Web of Science ®Google Scholar
• De Leon, D. D., Deng, S., Madani, R., Ahima, R. S., Drucker, D. J. and Stoffers, D. A. (2003). Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes. 52(2):365–371.
   PubMed Web of Science ®Google Scholar
• De Luis, D., Domingo, M., Romero, A., Gonzalez Sagrado, M., Pacheco, D., Primo, D. and Conde, R. (2012). Effects of duodenal-jejunal exclusion on beta cell function and hormonal regulation in Goto-Kakizaki rats. Am. J. Surg., 204(2):242–247.
   PubMed Web of Science ®Google Scholar
• Dirksen, C., Hansen, D. L., Madsbad, S., Hvolris, L. E., Naver, L. S., Holst, J. J. and Worm, D. (2010). Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: A case report. Diabetes Care. 33:375–377.
   PubMed Web of Science ®Google Scholar
• Dupre, J., Curtis, J.D., Unger, R.H., Waddell, R. W. and Beck, J. C. (1969). Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. Clin. Invest. 48(4):745–757.
   Google Scholar
• Edholm, T., Degerblad, M., Grybäck, P., Hilsted, L., Holst, J. J., Jacobsson, H., Efendic, S., Schmidt, P. T. and Hellström, P. M. (2010). Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterol Motil. 22(11):1191–1200.
   PubMed Web of Science ®Google Scholar
• Egshatyan, L., Kashtanova, D., Popenko, A., Tkacheva, O., Tyakht, A., Alexeev, D., Karamnova, N., Kostryukova, E., Babenko, V., Vakhitova, M. and Boytsov, S. (2016). Gut microbiota and diet in patients with different glucose tolerance. Endocr. Connect. 5(1):1–9.
   PubMed Web of Science ®Google Scholar
• Eickhoff, H., Louro, T. M., Matafome, P. N., Vasconcelos, F., Seiça, R. M., Castro, E. and Sousa, F. (2015). Amelioration of glycemic control by sleeve gastrectomy and gastric bypass in a lean animal model of type 2 diabetes: Restoration of gut hormone profile. Obes. Surg. 25(1):7–18.
   PubMed Web of Science ®Google Scholar
• English, P. J., Ashcroft, A., Patterson, M., Dovey, T. M., Halford, J. C., Harrison, J., Eccleston, D., Bloom, S. R., Ghatei, M. A. and Wilding, J. P. (2006).Fasting plasma peptide-YY concentrations are elevated but do not rise postprandially in type 2 diabetes. Diabetologia. 49(9):2219–2221.
   PubMed Web of Science ®Google Scholar
• Erdmann, J., Lippl, F., Wagenpfeil, S. and Schusdziarra, V. (2005). Differential association of basal and postprandial plasma ghrelin with leptin, insulin, and type 2 diabetes. Diabetes. 54(5):1371–1378.
   PubMed Web of Science ®Google Scholar
• Faerch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., Holst, J. J., Jørgensen, M. E. (2015).GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: The ADDITION-PRO study. Diabetes. 64(7):2513–2325.
   PubMed Web of Science ®Google Scholar
• Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., Atkins, A. R., Khvat, A., Schnabl, B., Yu, R. T., Brenner, D. A., Coulter, S., Liddle, C., Schoonjans, K., Olefsky, J. M., Saltiel, A. R., Downes, M. and Evans, R. M. (2015). Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21(2):159–165.
   PubMed Web of Science ®Google Scholar
• Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U. and Perfetti, R. (2002). Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 143(11):4397–4408.
   PubMed Web of Science ®Google Scholar
• Fernández-García, J. C., Murri, M., Coin-Aragüez, L., Alcaide, J., El Bekay, R. and Tinahones, F. J. (2014).GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects. Clin. Endocrinol (Oxf). 80(5):671–676.
   PubMed Web of Science ®Google Scholar
• Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R. and Anderson, C. M. (2011). BLOSSOM Clinical Trial Group.A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J. Clin. Endocrinol. Metab. 96(10):3067–3077.
   PubMed Web of Science ®Google Scholar
• Fleissner, C.K., Huebel, N., Abd El-Bary, M.M., Loh, G., Klaus, S., and Blaut, M. (2010). Absence of intestinal microbiota does not protect mice from dietinduced obesity. Br. J. Nutr. 104:919–929.
   PubMed Web of Science ®Google Scholar
• Flint, A., Raben, A., Astrup, A. and Holst, J. J. (1998). Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101(3):515–520.
   PubMed Web of Science ®Google Scholar
• Forbes, S., Stafford, S., Coope, G., Heffron, H., Real, K., Newman, R. and Cox, H. (2015). Selective FFA2 agonism appears to act via intestinal PYY to reduce transit and food intake but does not improve glucose tolerance in mouse models. Diabetes. 64(11):3763–3771.
   PubMed Web of Science ®Google Scholar
• Fosgerau, K., Jessen, L., Lind Tolborg, J., Østerlund, T., Schæffer Larsen, K., Rolsted, K. and Skovlund Ryge Neerup, T. (2013). The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice. Diab. Obes. Metab. 15(1):62–71.
   PubMed Web of Science ®Google Scholar
• Foxx-Orenstein, A., Camilleri, M., Stephens, D. and Burton, D. (2003). Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut. 52(11):1555–1561.
   PubMed Web of Science ®Google Scholar
• Fukui, M., Shiraishi, E., Tanaka, M., Senmaru, T., Sakabe, K., Harusato, I., Hasegawa, G. and Nakamura, N. (2009). Plasma serotonin is a predictor for deterioration of urinary albumin excretion in men with type 2 diabetes mellitus. Metabolism. 58(8):1076–1079.
   PubMed Web of Science ®Google Scholar
• Fulurija, A., Lutz, T. A., Sladko, K., Osto, M., Wielinga, P. Y., Bachmann, M. F. and Saudan, P. (2008). Vaccination against GIP for the treatment of obesity. PLoS ONE. 3(9):e3163.
   PubMed Web of Science ®Google Scholar
• Gault, V. A., Porter, D., Irwin, N. and Flatt, P. R. (2011). Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1–30) and GIP(1–42) in high fat fed mice. J. Endocrinology. 208(3):265–271.
   PubMed Web of Science ®Google Scholar
• Gauna, C., Delhanty, P. J. D., Hofland, L. J., Janssen, J. A. M. J. L., Broglio, F., Ross, R. J. M. and Van der Lely, A. J. (2005). Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J. Clin. Endocrinol. Metab. 90(2):1055–1060.
   PubMed Web of Science ®Google Scholar
• Gehlert, D. R. and Shaw, J. (2014). 5-Hydroxytryptamine 1A (5HT1A) receptors mediate increases in plasma glucose independent of corticosterone. Eur. J. Pharmacol. 745:91–7.
   PubMed Web of Science ®Google Scholar
• Geloneze, B., Lima, M. M., Pareja, J. C., Barreto, M. R. and Magro, D. O. (2013). Association of insulin resistance and GLP-2 secretion in obesity: A pilot study. Arq. Bras. Endocrinol. Metabol. 57(8):632–635.
   PubMedGoogle Scholar
• Geurts, L., Lazarevic, V., Derrien, M., et al. (2011). Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: Impact on apelin regulation in adipose tissue. Front Microbiol. 2:1–17.
   PubMed Web of Science ®Google Scholar
• Glaser, B., Raveh, Y., Norynberg, C., Berry, E., Lavielle, R., Nathan, C. and Cerasi, E. (1992). Acute and chronic effects of dexfenfluramine on glucose and insulin response to intravenous glucose in diabetic and non-diabetic obese subjects. Diabetes Res. 19(4):165–176.
   PubMedGoogle Scholar
• World Health Organization, Global report on diabetes. World Health Organization, Geneva, 2016.
   Google Scholar
• Gniuli, D., Calcagno, A., Dalla Libera, L., Calvani, R., Leccesi, L., Caristo, M. E. and Mingrone, G. (2010). High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats. Diabetologia. 53(10):2233–2240.
   PubMed Web of Science ®Google Scholar
• González-Ortiz, M., Martínez-Abundis, E., Mercado-Sesma, A. R. and Álvarez-Carrillo, R. (2015). Effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes. Diabetes Res. Clin. Pract. 108(1):e11–e13.
   PubMed Web of Science ®Google Scholar
• Granata, R., Settanni, F., Biancone, L., Trovato, L., Nano, R., Bertuzzi, F. and Muccioli, G. (2007). Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: Involvement of 3′,5′-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inosit. Endocrinology. 148(2):512–529.
   PubMed Web of Science ®Google Scholar
• Grill, V., Gutniak, M., Roovete, A. and Efendić, S. (1984). A stimulating effect of glucose on somatostatin release is impaired in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 59(2):293–297.
   PubMed Web of Science ®Google Scholar
• Groop, P. H., Fyhrquist, F. and Groop, L. C. (1985).Effect of serial test meals on plasma immunoreactive GIP in non-insulin dependent diabetic patients and non-diabetic controls. Scand. J. Clin. Lab. Invest. 45(2):115–22.
   PubMed Web of Science ®Google Scholar
• Guo, Y., Ma, L., Enriori, P. J., Koska, J., Franks, P. W., Brookshire, T., Cowley, M. A., Salbe, A. D., Delparigi, A. and Tataranni, P. A. (2006). Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans. Obesity (Silver Spring). 14(9):1562–1570.
   PubMed Web of Science ®Google Scholar
• Gutniak, M., Grill, V., Roovete, A. and Efendic, S. (1989). Impaired somatostatin response to orally administered glucose in type II diabetes entails both somatostatin-28 and -14 and is associated with deranged metabolic control. Acta Endocrinol. (Copenh) 121(3):322–326.
   PubMedGoogle Scholar
• Gutzwiller, J. P, Drewe, J., Hildebrand, P., Rossi, L., Lauper, J. Z. and Beglinger, C. (1994). Effect of intravenous human gastrin-releasing peptide on food intake in humans. Gastroenterology. 106(5):1168–1173.
   PubMed Web of Science ®Google Scholar
• Gutzwiller, J. P., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J. and Beglinger, C. (1999). Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 276(5 Pt 2):R1541–R1544.
   PubMed Web of Science ®Google Scholar
• Guy-Grand, B., Apfelbaum, M., Crepaldi, G., Gries, A., Lefebvre, P. and Turner, P. (1989). International trial of long-term dexfenfluramine in obesity. Lancet. 2(8672):1142–1145.
   PubMed Web of Science ®Google Scholar
• Hauge-Evans, A. C., Bowe, J., Franklin, Z. J., Hassan, Z. and Jones, P. M. (2015). Inhibitory effect of somatostatin on insulin secretion is not mediated via the CNS. J. Endocrinology. 225(1):19–26.
   PubMed Web of Science ®Google Scholar
• Hauge-Evans, A. C., King, A. J., Carmignac, D., Richardson, C. C., Robinson, I. C. A. F., Low, M. J. and Jones, P. M. (2009). Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes. 58(2) 403–411.
   PubMed Web of Science ®Google Scholar
• He, C., Shan, Y. and Song, W.(2015). Targeting gut microbiota as a possible therapy for diabetes. Nutr. Res. 35(5):361–367.
   PubMed Web of Science ®Google Scholar
• Herzog, H. (2003). Neuropeptide Y and energy homeostasis: Insights from Y receptor knockout models. Eur. J. Pharmacology. 480(1–3):21–29.
   PubMed Web of Science ®Google Scholar
• Hildebrandt, M. A, Hoffmann, C., Sherrill-Mix, S. A, et al. (2009). High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 137:1716–1724.e1–2.
   Web of Science ®Google Scholar
• Hinke, S. A., Gelling, R. W., Pederson, R. A., Manhart, S., Nian, C., Demuth, H.-U. and McIntosh, C. H. S. (2002). Dipeptidyl peptidase IV-resistant [D-Ala2] glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes. 51(3):652–661.
   PubMed Web of Science ®Google Scholar
• Hojberg, P. V. et al. (2009). Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 52:199–207.
   PubMed Web of Science ®Google Scholar
• Holst, J. J., Jensen, S. L., Knuhtsen, S. and Nielsen, O. V (1983). Autonomic nervous control of pancreatic somatostatin secretion. Am. J. Physiol. 245:E542–E548.
   PubMed Web of Science ®Google Scholar
• Iida, A., Seino, Y., Fukami, A., Maekawa, R., Yabe, D., Shimizu, S. and Hayashi, Y. (2016). Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin. Diabetologia. 59(7):1533–1541.
   PubMed Web of Science ®Google Scholar
• Inci, F., Atmaca, M., Ozturk, M., Yildiz, S., Koceroglu, R., Sekeroglu, R., Ipekci, S.H. and Kebapcilar, L. (2014). Pantoprazole may improve beta cell function and diabetes mellitus. J. Endocrinol Invest. 37(5):449–454.
   PubMed Web of Science ®Google Scholar
• Iordanidou, M., Tavridou, A., Petridis, I., Arvanitidis, K.I., Christakidis, D., Vargemezis, V. and Manolopoulos, V. G. (2010). The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes. Clin. Chim. Acta. 411(3–4):167–171.
   PubMed Web of Science ®Google Scholar
• Irwin, N. and Flatt, P. R. (2009). Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia. 52(9):1724–1731.
   PubMed Web of Science ®Google Scholar
• Irwin, N., Hunter, K., Montgomery, I. A. and Flatt, P. R. (2013a). Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice. Diabetes, Obesity Metabolism. 15(7):650–659.
   PubMed Web of Science ®Google Scholar
• Irwin, N., Montgomery, I. A., Moffett, R. C. and Flatt, P. R. (2013). Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice. Biochem. Pharmacology. 85(1):81–91.
   PubMed Web of Science ®Google Scholar
• Itoh, M., Hirooka, Y. and Nihei, N. (1983). Response of plasma somatostatin-like immunoreactivity (SLI) to a 75 g oral glucose tolerance test in normal subjects and patients with impaired glucose tolerance. Acta. Endocrinol. (Copenh). 104(4):468–474.
   PubMedGoogle Scholar
• Jacoby, J. H. and Bryce, G. F. (1978). The acute pharmacologic effects of serotonin on the release of insulin and glucagon in the intact rat. Arch. Intl. Pharmacodyn. Thérap. 235(2):254–270.
   PubMedGoogle Scholar
• Jonderko, G., Jonderko, K. and Gołab, T. (1989). Effect of somatostatin-14 on gastric emptying and on gastrin and insulin release after ingestion of a mixed solid-liquid meal in man. Mater. Med. Pol. 21(3):174–180.
   PubMedGoogle Scholar
• Jones, I. R., Owens, D. R., Moody, A. J., Luzio, S. D., Morris, T. and Hayes, T. M. (1987). The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia. 30(9):707–712.
   PubMed Web of Science ®Google Scholar
• Joshi, S., Tough, I. R. and Cox, H. M. (2013). Endogenous PYY and GLP-1 mediate l-glutamine responses in intestinal mucosa. Br. J. Pharmacol. 170(5):1092–1101.
   PubMed Web of Science ®Google Scholar
• Julio-Pieper, M., O'Mahony, C. M., Clarke, G., Bravo, J. A., Dinan, T. G. and Cryan, J. F. (2012). Chronic stress-induced alterations in mouse colonic 5-HT and defecation responses are strain dependent. Stress. 15:218–226.
   PubMed Web of Science ®Google Scholar
• Kampmann, K., Ueberberg, S., Menge, B. A., Breuer, T. G. K., Uhl, W., Tannapfel, A. and Meier, J. J. (2016). Abundance and turnover of GLP-1 producing L-cells in ileal mucosa are not different in patients with and without type 2 diabetes. Metab.: Clin. Exp., 65(3):84–91.
   PubMed Web of Science ®Google Scholar
• Karlsson, F., Tremaroli, V., Nielsen, J. and Bäckhed, F. (2013a). Assessing the human gut microbiota in metabolic diseases. Diabetes. 62(10):3341–3349.
   PubMed Web of Science ®Google Scholar
• Karlsson, F.H., Tremaroli, V., Nookaew, I., et al. (2013b). Gut metagenome in European women with normal, impaired and diabeteic glucose control. Nature. 498:99–103.
   PubMed Web of Science ®Google Scholar
• Katsuki, A., Urakawa, H., Gabazza, E.C., Murashima, S., Nakatani, K., Togashi, K., Yano, Y., Adachi, Y. and Sumida, Y. (2004). Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. Eur. J. Endocrinol. 151(5):573–577.
   PubMed Web of Science ®Google Scholar
• Kim, S.-J., Nian, C., Karunakaran, S., Clee, S. M., Isales, C. M. and McIntosh, C. H. S. (2012). GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PloS One. 7(7):e40156.
   PubMed Web of Science ®Google Scholar
• Kissileff, H. R., Pi-Sunyer, F. X., Thornton, J. and Smith, G. P. (1981). C-terminal octapeptide of cholecystokinin decreases food intake in man. Am. J. Clin. Nutr. 34(2):154–160.
   PubMed Web of Science ®Google Scholar
• Knop, F. K., Vilsboll, T., Madsbad, S., Holst, J. J., and Krarup, T. (2007). Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia. 50: 797–805.
   PubMed Web of Science ®Google Scholar
• Kojima, M. (2005). Ghrelin: Structure and function. Physiol. Rev. 85(2):495–522.
   PubMed Web of Science ®Google Scholar
• Kootte, R. S, Vrieze, A., Holleman, F., Dallinga-Thie, G. M., Zoetendal, E. G., de Vos, W. M., Groen, A. K., Hoekstra, J. B., Stroes, E. S. and Nieuwdorp, M. (2012).The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diab. Obes. Metab. 14(2):112–120.
   PubMed Web of Science ®Google Scholar
• Kreymann, B., Williams, G., Ghatei, M. A. and Bloom, S. R. (1987).Glucagon-like peptide-1 7–36: A physiological incretin in man. Lancet. 2(8571):1300–1304.
   PubMed Web of Science ®Google Scholar
• Kring, S. I., Werge, T., Holst, C., Toubro, S., Astrup, A., Hansen, T., Pedersen, O. and Sorensen, T. I. (2009). Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes. PLoS One. 4(8):e6696.
   PubMed Web of Science ®Google Scholar
• Larhammar, D. (1996). Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regulatory Peptides. 62(1):1–11.
   PubMedGoogle Scholar
• Larsen, N., Vogensen, F. K., van den Berg, F. W., Nielsen, D. S., Andreasen, A. S., Pedersen, B. K., Al-Soud, W. A., Sørensen, S. J., Hansen, L. H. and Jakobsen, M. (2010).Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 5:e9085.
   PubMed Web of Science ®Google Scholar
• Lastya, A., Saraswati, M. R. and Suastika, K. (2014). The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus. BMC Res. Notes 7:849.
   PubMedGoogle Scholar
• Lavine, J. A., Kibbe, C. R., Baan, M., Sirinvaravong, S., Umhoefer, H. M., Engler, K. A., and Davis, D. B. (2015). Cholecystokinin expression in the β-cell leads to increased β-cell area in aged mice and protects from streptozotocin-induced diabetes and apoptosis. Am. J. Physiol. Endocrinol. Metab. 309(10):E819–E828.
   Google Scholar
• Lavine, J. A., Raess, P. W., Davis, D. B., Rabaglia, M. E., Presley, B. K., Keller, M. P. and Attie, A. D. (2008). Overexpression of pre-pro-cholecystokinin stimulates beta-cell proliferation in mouse and human islets with retention of islet function. Molec. Endocrinol. (Baltimore, Md.). 22(12):2716–2728.
   PubMed Web of Science ®Google Scholar
• Lavine, J. A., Raess, P. W., Stapleton, D. S., Rabaglia, M. E., Suhonen, J. I., Schueler, K. L., and Attie, A. D. (2010). Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival. Endocrinology. 151(8):3577–3588.
   PubMed Web of Science ®Google Scholar
• Le, T. K., Hosaka, T., Nguyen, T. T., Kassu, A., Dang, T. O., Tran, H. B, Pham, T. P., Tran, Q. B., Le, T. H., Pham, X. D. (2015). Bifidobacterium species lower serum glucose, increase expressions of insulin signaling proteins, and improve adipokine profile in diabetic mice. Biomed. Res. 36(1):63–70.
   PubMed Web of Science ®Google Scholar
• Lee, S., Yabe, D., Nohtomi, K., Takada, M., Morita, R., Seino, Y. and Hirano, T. (2010). Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J. 57(2):119–126.
   PubMed Web of Science ®Google Scholar
• Legakis, I. N., Tzioras, C. and Phenekos, C. (2003). Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes. Diabetes Care. 26(1):252.
   PubMed Web of Science ®Google Scholar
• Li, C., Li, X., Han, H., Cui, H., Peng, M., Wang, G. and Wang, Z. (2016). Effect of probiotics on metabolic profiles in type 2 diabetes mellitus: A meta-analysis of randomized, controlled trials. Medicine (Baltimore). 95(26):e4088.
   PubMed Web of Science ®Google Scholar
• Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A. and Drucker, D. J. (2003). Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 278(1):471–478.
   PubMed Web of Science ®Google Scholar
• Liddle, R. A., Rushakoff, R. J., Morita, E. T., Beccaria, L., Carter, J. D. and Goldfine, I. D. (1988). Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans. J. Clin. Invest. 81(6):1675–1681.
   PubMed Web of Science ®Google Scholar
• Lieverse, R. J., Jansen, J. B., Masclee, A. M. and Lamers, C. B. (1995). Effects of somatostatin on human satiety. Neuroendocrinology. 61(2):112–116.
   PubMed Web of Science ®Google Scholar
• Ling, Z., Wu, D., Zambre, Y., Flamez, D., Drucker, D. J., Pipeleers, D. G. and Schuit, F. C. (2001). Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Archiv. 438(4):382–387.
   PubMed Web of Science ®Google Scholar
• Little, T. J., Horowitz, M. and Feinle-Bisset, C. (2007). Modulation by high-fat diets of gastrointestinal function and hormones associated with the regulation of energy intake: Implications for the pathophysiology of obesity. Am. J. Clin. Nutr. 86(3):531–541.
   PubMed Web of Science ®Google Scholar
• Long, R. G., Christofides, N. D., Fitzpatrick, M. L., O'Shaughnessy, D. J. and Bloom, S. R. (1982). Effects of intravenous somatostatin and motilin on the blood glucose and hormonal response to oral glucose. Eur. J. Clin. Invest. 12(4):331–336.
   PubMed Web of Science ®Google Scholar
• Lopes, L. S., Schwartz, R. P., Ferraz-de-Souza, B., da Silva, M. E., Corrêa, P. H. and Nery, M. (2015). The role of enteric hormone GLP-2 in the response of bone markers to a mixed meal in postmenopausal women with type 2 diabetes mellitus. Diabetol Metab. Syndr. 7:13.
   PubMed Web of Science ®Google Scholar
• Lund, A., Vilsbøll, T., Bagger, J. I., Holst, J. J. and Knop, F. K. (2011). The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am. J. Physiol. Endocrinol Metab. 300(6):E1038–E1046.
   PubMed Web of Science ®Google Scholar
• Ma, H. T., Kato, M. and Tatemoto, K. (1996). Effects of pancreastatin and somatostatin on secretagogues-induced rise in intracellular free calcium in single rat pancreatic islet cells. Regulatory Peptides. 61(2):143–148.
   PubMedGoogle Scholar
• Marco, J., Correas, I., Zulueta, M. A., Vincent, E., Coy, D. H., Comaru-Schally, A. M. and Schally, A. V., Rodríguez-Arnao, M. D., Gómez-Pan, A. (1983). Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man. Horm Metab Res. 15(8):363–366.
   PubMed Web of Science ®Google Scholar
• Markianos, M., Evangelopoulos, M. E., Koutsis, G. and Sfagos, C. (2013). Elevated CSF serotonin and dopamine metabolite levels in overweight subjects. Obesity (Silver Spring). 21(6):1139–1142.
   PubMed Web of Science ®Google Scholar
• Marks, S. J., Moore, N. R., Clark, M. L., Strauss, B. J. and Hockaday, T. D.(1996). Reduction of visceral adipose tissue and improvement of metabolic indices: Effect of dexfenfluramine in NIDDM. Obes. Res. 4(1):1–7.
   PubMedGoogle Scholar
• Matikainen, N., Björnson, E., Söderlund, S., Borén, C., Eliasson, B., Pietiläinen, K. H., Bogl, L. H., Hakkarainen, A., Lundbom, N., Rivellese, A., Riccardi, G., Després, J. P., Alméras, N., Holst, J. J., Deacon, C. F., Borén, J. and Taskinen, M. R. (2016). Minor contribution of endogenous GLP-1 and GLP-2 to postprandial lipemia in obese men. PLoS One. 11(1):e0145890.
   PubMed Web of Science ®Google Scholar
• Mazidi, M., Rezaie, P., Kengne, A. P., Mobarhan, M. G. and Ferns, G. A. (2016). Gut microbiome and metabolic syndrome. Diabetes Metab Syndr. 10(2–1):S150–S157.
   PubMed Web of Science ®Google Scholar
• Mefford, I. N., Mefford, J. T. and Burris, C. A. (2012). Improved diabetes control and pancreatic function in a type 2 diabetic after omeprazole administration. Case Reports in Endocrinology. 2012:468609.
   PubMedGoogle Scholar
• Meier, J. J., Gallwitz, B., Schmidt, W. E. and Nauck, M. A.(2002). Glucagon-like peptide 1 as a regulator of food intake and body weight: Therapeutic perspectives. Eur. J. Pharmacol. 440(2–3):269–279.
   PubMed Web of Science ®Google Scholar
• Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E. and Nauck, M. A. (2003). Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia. 46(6):798–801.
   PubMed Web of Science ®Google Scholar
• Meier, J. J., Hücking, K., Holst, J. J., Deacon, C. F., Schmiegel, W. H. and Nauck, M. A. (2001). Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes. 50(11):2497–2504.
   PubMed Web of Science ®Google Scholar
• Meier, J. J., Nauck, M. A., Pott, A., Heinze, K., Goetze, O., Bulut, K., Schmidt, W. E., Gallwitz, B. and Holst, J. J. (2006). Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 130(1):44–54.
   PubMed Web of Science ®Google Scholar
• Meier, J. J., Gallwitz, B., Kask, B., Deacon, C. F., Holst, J. J., Schmidt, W. E. and Nauck, M. A. (2004). Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes. 53(3):S2204.
   Web of Science ®Google Scholar
• Migdalis, L., Thomaides, T., Chairopoulos, C., Kalogeropoulou, C., Charalabides, J. and Mantzara, F. (2001). Changes of gastric emptying rate and gastrin levels are early indicators of autonomic neuropathy in type II diabetic patients. Clin. Auton. Res. 11(4):259–263.
   PubMed Web of Science ®Google Scholar
• Milewicz, A., Mikulski, E. and Bidzińska, B. (2000). Plasma insulin, cholecystokinin, galanin, neuropeptide Y and leptin levels in obese women with and without type 2 diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 24(2):S152–S153.
   PubMed Web of Science ®Google Scholar
• Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H. and Seino, Y. (2002). Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Med. 8(7):738–742.
   PubMed Web of Science ®Google Scholar
• Miyazaki, K., Funakoshi, A. and Ibayashi, H. (1986).Plasma somatostatin-like immunoreactivity responses to a mixed meal and the heterogeneity in healthy and non-insulin-dependent (NIDDM) diabetics. Endocrinol Jpn. 33(1):51–59.
   PubMedGoogle Scholar
• Monteleone, P., Piscitelli, F., Scognamiglio, P., Monteleone, A. M., Canestrelli, B., Di Marzo, V. and Maj, M. (2012). Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: A pilot study. J. Clin. Endocrinol Metab. 97(6):E917–E924.
   PubMed Web of Science ®Google Scholar
• Mul, J. D., Begg, D. P., Barrera, J. G., Li, B., Matter, E. K., D'Alessio, D. A. and Sandoval, D. A. (2013). High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats. Am. J. Physiol. Regul. Integr. Comparat. Physiol. 305(1):R68–R77.
   PubMed Web of Science ®Google Scholar
• Müller, T. D., Nogueiras, R., Andermann, M. L., Andrews, Z. B., Anker, S. D., Argente, J. and Tschöp, M. H. (2016). Ghrelin. Molec. Metab. 4(6):437–460.
   Web of Science ®Google Scholar
• Mumphrey, M. B., Patterson, L. M., Zheng, H. and Berthoud, H. R. (2013). Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1-, 5-HT-, and neurotensin-expressing enteroendocrine cells in rats. Neurogastroenterol. Motility Off. J. Eur. Gastrointest. Motil. Soc. 25(1):e70–e79.
   PubMed Web of Science ®Google Scholar
• Nakano, I., Funakoshi, A., Shinozaki, H., Miyazaki, K., Ibayashi, H., Tateish, I. K. and Hamaoka. (1986). Thigh plasma cholecystokinin response following ingestion of test meal by patients with non-insulin dependent diabetes mellitus. Regul. Pept. 14(3):229–236.
   PubMedGoogle Scholar
• Nam, J. S., Nam, J. Y., Yoo, J. S., Cho, M., Park, J. S., Ahn, C. W., … Lee, H. C. (2010). The effect of mosapride (5HT-4 receptor agonist) on insulin sensitivity and GLUT4 translocation. Diabetes Res. Clin. Pract. 87(3):329–334.
   PubMed Web of Science ®Google Scholar
• Natalicchio, A., De Stefano, F., Orlando, M. R., Melchiorre, M., Leonardini, A., Cignarelli, A. and Giorgino, F. (2010). Exendin-4 prevents c-Jun N-terminal protein kinase activation by tumor necrosis factor-alpha (TNFalpha) and inhibits TNFalpha-induced apoptosis in insulin-secreting cells. Endocrinology. 151(5):2019–2029.
   PubMed Web of Science ®Google Scholar
• Natalicchio, A., Labarbuta, R., Tortosa, F., Biondi, G., Marrano, N., Peschechera, A. and Giorgino, F. (2013). Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and the MKK4/7 stress kinase signalling pathway. Diabetologia. 56(11):2456–2466.
   PubMed Web of Science ®Google Scholar
• Nauck, M., Stöckmann, F., Ebert, R. and Creutzfeldt, W. (1986). Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 29(1):46–52.
   PubMed Web of Science ®Google Scholar
• Nauck, M. A, Niedereichholz, U., Ettler, R., Holst, J. J., Orskov, C., Ritzel, R. and Schmiegel, W. H. (1997). Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 273(5 Pt 1):E981–E988.
   PubMed Web of Science ®Google Scholar
• Nauck, M. A., Bartels, E., Orskov, C., Ebert, R. and Creutzfeldt, W. (1993). Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol Metab. 76(4):912–917.
   PubMed Web of Science ®Google Scholar
• Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R. and Creutzfeldt, W.(1993). Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91(1):301–307.
   PubMed Web of Science ®Google Scholar
• Nauck, M. A., Kleine, N., Orskov, C., Holst, J. J., Willms, B. and Creutzfeldt, W. (1993). Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36(8):741–744.
   PubMed Web of Science ®Google Scholar
• Neish, A. S. (2009). Microbes in gastrointestinal health and disease. Gastroenterology. 136: 65–80.
   PubMed Web of Science ®Google Scholar
• Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., et al. (2012). Host-gut microbiota metabolic interactions. Science. 336:1262–1267.
   PubMed Web of Science ®Google Scholar
• Omar, B., Ahlkvist, L., Yamada, Y., Seino, Y. and Ahrén, B. (2016). Incretin hormone receptors are required for normal beta cell development and function in female mice. Peptides. 79:58–65.
   PubMed Web of Science ®Google Scholar
• Orskov, C., Holst, J. J. and Nielsen, O. V. (1988). Effect of truncated glucagon-like peptide-1 [proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 123(4):2009–2013.
   PubMed Web of Science ®Google Scholar
• Pace, C. S. and Tarvin, J. T. (1981). Somatostatin: Mechanism of action in pancreatic islet beta-cells. Diabetes. 30(10):836–42.
   PubMed Web of Science ®Google Scholar
• Pace, C. S., Murphy, M., Conant, S. and Lacy, P. E. (1977). Somatostatin inhibition of glucose-induced electrical activity in cultured rat islet cells. Am. J. Physiol. 233(5):C165–C171.
   PubMed Web of Science ®Google Scholar
• Panwar, H., Rashmi, H. M., Batish, V. K., et al. (2013). Probiotics as potential biotherapeutics in the management of type 2 diabetes: Prospects and perspectives. Diab./Metab. Res. Rev. 29(2):103–112.
   PubMed Web of Science ®Google Scholar
• Pedersen, H. K., Gudmundsdottir, V., Nielsen, H. B., Hyotylainen, T., Nielsen, T., Jensen, B. A., Forslund, K., Hildebrand, F., Prifti, E., Falony, G., Le Chatelier, E., Levenez, F., Doré, J., Mattila, I., Plichta, D. R., Pöhö, P., Hellgren, L.I., Arumugam, M., Sunagawa, S., Vieira-Silva, S., Jørgensen, T, Holm, J. B., Trošt, K., Meta, HIT, Consortium, Kristiansen, K., Brix, S., Raes, J., Wang, J., Hansen, T., Bork, P., Brunak, S., Oresic, M., Ehrlich, S. D., Pedersen, O. (2016). Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 535(7612):376–381.
   PubMed Web of Science ®Google Scholar
• Pedersen, J., Ugleholdt, R. K., Jorgensen, S. M., Windeløv, J. A., Grunddal, K. V, Schwartz, T. W., Füchtbauer, E. M., Poulsen, S. S., Holst, P. J. and Holst, J. J. (2013). Glucose metabolism is altered after loss of L cells and α-cells but not influenced by loss of K cells. Am. J. Physiol. Endocrinol. Metab. 304:E60–E73.
   PubMed Web of Science ®Google Scholar
• Pestell, R. G., Crock, P. A., Ward, G. M., Alford, F. P., Best, J. D. (1989). Fenfluramine increases insulin action in patients with NIDDM. Diab. Care. 12(4):252–258.
   PubMed Web of Science ®Google Scholar
• Portela-Gomes, G. M., Grimelius, L., Westermark, P. and Stridsberg, M. (2010). Somatostatin receptor subtypes in human type 2 diabetic islets. Pancreas. 39(6):836–842.
   PubMed Web of Science ®Google Scholar
• Pöykkö, S. M., Kellokoski, E., Hörkkö, S., Kauma, H., Kesäniemi, Y. A. and Ukkola, O. (2003). Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 52(10):2546–2553.
   PubMed Web of Science ®Google Scholar
• Price, J. C., Kelley, D. E., Ryan, C. M., Meltzer, C. C., Drevets, W. C., Mathis, C. A., Mazumdar, S. and Reynolds, C. F. (2002). Evidence of increased serotonin-1A receptor binding in type 2 diabetes: A positron emission tomography study. Brain Res. 927(1):97–103.
   PubMed Web of Science ®Google Scholar
• Proietto, J., Thorburn, A. W., Fabris, S. and Harrison, L. C. (1994). Effects of dexfenfluramine on glucose turnover in non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 23(2):127–134.
   PubMed Web of Science ®Google Scholar
• Psichas, A., Sleeth, M. L., Murphy, K. G., Brooks, L., Bewick, G. A., Hanyaloglu, A. C. and Frost, G. (2015). The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int. J. Obesity. 39(3):424–429.
   PubMed Web of Science ®Google Scholar
• Qin, J., Li, Y., Cai, Z., et al. (2012).A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 490:55–60.
   PubMed Web of Science ®Google Scholar
• Rachman, J., Barrow, B. A., Levy, J. C. and Turner, R. C. (1997). Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 40(2):205–211.
   PubMed Web of Science ®Google Scholar
• Rachman, J., Gribble, F. M., Barrow, B. A., Levy, J. C., Buchanan, K. D. and Turner, R. C.(1996). Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7–36) amide in patients with NIDDM. Diabetes. 45(11):1524–1530.
   PubMed Web of Science ®Google Scholar
• Rehfeld, J. F. (1971). Effect of gastrin and its C-terminal tetrapeptide on insulin secretion in man. Acta Endocrinol (Copenh). 66(1):169–176.
   PubMedGoogle Scholar
• Rehfeld, J. F. and Stadil, F. (1973). The effect of gastrin on basal- and glucose-stimulated insulin secretion in man. J. Clin. Invest. 52(6):1415–1426.
   PubMed Web of Science ®Google Scholar
• Rooman, I. and Bouwens, L. (2004). Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan. Diabetologia. 47(2):259–265.
   PubMed Web of Science ®Google Scholar
• Rubino, F., R'bibo, S. L., del Genio, F., Mazumdar, M. and McGraw, T. E. (2012). Metabolic surgery: The role of the gastrointestinal tract in diabetes mellitus. Nat. Rev. Endocrinol. 6(2):102–109.
   Web of Science ®Google Scholar
• Rubino, F., Zizzari, P., Tomasetto, C., Bluet-Pajot, M. T., Forgione, A., Vix, M. and Marescaux, J. (2005). The role of the small bowel in the regulation of circulating ghrelin levels and food intake in the obese Zucker rat. Endocrinology. 146(4):1745–1751.
   PubMed Web of Science ®Google Scholar
• Rushakoff, R. A., Goldfine, I. D., Beccaria, L. J., Mathur, A., Brand, R. J. and Liddle, R. A. (1993). Reduced postprandial cholecystokinin (CCK) secretion in patients with noninsulin-dependent diabetes mellitus: Evidence for a role for CCK in regulating postprandial hyperglycemia. J. Clin. Endocrinol. Metab. 76(2):489–493.
   PubMed Web of Science ®Google Scholar
• Rushakoff, R. J, Goldfine, I. D., Carter, J. D. and Liddle, R. A. (1987). Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans. J. Clin. Endocrinol. Metab. 65(3):395–401.
   PubMed Web of Science ®Google Scholar
• Sarson, D. L., Wood, S. M., Kansal, P. C. and Bloom, S. R. (1984). Glucose-dependent insulinotropic polypeptide augmentation of insulin. Physiology or pharmacology?. Diabetes. 33(4):389–393.
   PubMed Web of Science ®Google Scholar
• Sasaki, S., Miyatsuka, T., Matsuoka, T., Takahara, M., Yamamoto, Y., Yasuda, T. and Shimomura, I. (2015). Activation of GLP-1 and gastrin signalling induces in vivo reprogramming of pancreatic exocrine cells into beta cells in mice. Diabetologia. 58(11):2582–2591.
   PubMed Web of Science ®Google Scholar
• Scheen, A. J., Paolisso, G., Salvatore, T., Lefèbvre, P. J. (1991). Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care. 14(4):325–332.
   PubMed Web of Science ®Google Scholar
• Schirra, J., Houck, P., Wank, U., Arnold, R., Göke, B. and Katschinski, M. (2000). Effects of glucagon-like peptide-1(7–36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut. 46(5):622–631.
   PubMed Web of Science ®Google Scholar
• Schmidt, W. E., Siegel, E. G. and Creutzfeldt, W. (1985). Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia. 28(9): 704–707.
   PubMed Web of Science ®Google Scholar
• Scrocchi, L. A., Hill, M. E., Saleh, J., Perkins, B. and Drucker, D. J. (2000). Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Diabetes. 49(9):1552–1560.
   PubMed Web of Science ®Google Scholar
• Sekhar, M. S. and Unnikrishnan, M. K. (2015). Probiotic research for diabetes prevention. Nutrition. 31(1):248.
   PubMed Web of Science ®Google Scholar
• Shi, X., Zhou, F., Li, X., Chang, B., Li, D., Wang, Y. and Guan, X. (2013). Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons. Cell Metab. 18(1):86–98.
   PubMed Web of Science ®Google Scholar
• Shi, Y.-C., Loh, K., Bensellam, M., Lee, K., Zhai, L., Lau, J. and Herzog, H. (2015). Pancreatic PYY is critical in the control of insulin secretion and glucose homeostasis in female mice. Endocrinology. 156(9):3122–3136.
   PubMed Web of Science ®Google Scholar
• Shimizu, H., Eldar, S., Heneghan, H. M., Schauer, P. R., Kirwan, J. P. and Brethauer, S. A. (2014). The effect of selective gut stimulation on glucose metabolism after gastric bypass in the Zucker diabetic fatty rat model. Surgery for obesity and related diseases. Off. J. Am. Soc. Bariatr. Surg. 10(1):29–35.
   Google Scholar
• Singh, P. K., Hota, D., Dutta, P., Sachdeva, N., Chakrabarti, A., Srinivasan, A., Singh, I. and Bhansali, A. (2012). Pantoprazole improves glycemic control in type 2 diabetes: A randomized, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 97(11):E2105–E2108.
   PubMed Web of Science ®Google Scholar
• Skrha, J., Hilgertová, J., Jarolímková, M., Kunešová, M. and Hill, M. (2010). Meal test for glucose-dependent insulinotropic peptide (GIP) in obese and type 2 diabetic patients. Physiol. Res. 59(5):749–755.
   PubMed Web of Science ®Google Scholar
• Song, I., Patel, O., Himpe, E., Muller, C. J. F. and Bouwens, L. (2015). Beta cell mass restoration in alloxan-diabetic mice treated with EGF and gastrin. PloS One. 10(10):e0140148.
   PubMed Web of Science ®Google Scholar
• Sorensen, L. B., Flint, A., Raben, A., Hartmann, B., Holst, J. J. and Astrup, A. (2003). No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. J. Int. Assoc. Study Obesity. 27(4):450–456.
   PubMed Web of Science ®Google Scholar
• Starosel'tseva, L. K., Kniazeva, A. P., Belovalova, I. M. and Abduraimova, G. R. (1988).The role of gastrin in regulating insulin and glucagon secretion in patients with diabetes mellitus. Probl. Endokrinol (Mosk). 34(4):20–25.
   PubMedGoogle Scholar
• Steiner, C., Othman, A., Saely, C. H., Rein, P., Drexel, H., von Eckardstein, A., Rentsch, K. M. (2011). Bile acid metabolites in serum: Intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PloS One. 6:e25006.
   PubMed Web of Science ®Google Scholar
• Steinert, R. E., Poller, B., Castelli, M. C., Drewe, J. and Beglinger, C. (2010). Oral administration of glucagon-like peptide 1 or peptide YY 3–36 affects food intake in healthy male subjects. Am. J. Clin. Nutr. 6(11):e25006.
   Google Scholar
• Stenman, L. K., Waget, A., Garret, C., Klopp, P., Burcelin, R., Lahtinen, S. (2014). Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. Benef Microbes. 5(4):437–445.
   PubMed Web of Science ®Google Scholar
• Stewart, G. O., Stein, G. R., Davis, T. M. and Findlater, P. (1993). Dexfenfluramine in type II diabetes: Effect on weight and diabetes control. Med. J. Aust. 158(3):167–169.
   PubMed Web of Science ®Google Scholar
• Strowski, M. Z., Parmar, R. M., Blake, A. D. and Schaeffer, J. M. (2000). Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: An in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology. 141(1):111–117.
   PubMed Web of Science ®Google Scholar
• Suarez-Pinzon, W. L., Power, R. F., Yan, Y., Wasserfall, C., Atkinson, M. and Rabinovitch, A. (2008). Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes. 57(12):3281–3288.
   PubMed Web of Science ®Google Scholar
• Sun, Y., Asnicar, M., Saha, P. K., Chan, L. and Smith, R. G. (2006). Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab. 3(5):379–386.
   PubMed Web of Science ®Google Scholar
• Tamborlane, W. V., Sherwin, R. S., Hendler, R. and Felig, P. (1977). Metabolic effects of somatostatin in maturity-onset diabetes. N. Engl. J. Med. 297(4):181–183.
   PubMed Web of Science ®Google Scholar
• Tatarkiewicz, K., Hargrove, D. M., Jodka, C. M., Gedulin, B. R., Smith, P. A., Hoyt, J. A., and Parkes, D. G. (2014). A novel long-acting glucose-dependent insulinotropic peptide analogue: Enhanced efficacy in normal and diabetic rodents. Diab. Obes. Metab. 16(1):75–85.
   PubMed Web of Science ®Google Scholar
• Tellez, N. and Montanya, E. (2014). Gastrin induces ductal cell dedifferentiation and beta-cell neogenesis after 90% pancreatectomy. J. Endocrinol. 223(1):67–78.
   PubMed Web of Science ®Google Scholar
• Tellez, N., Joanny, G., Escoriza, J., Vilaseca, M. and Montanya, E. (2011). Gastrin treatment stimulates beta-cell regeneration and improves glucose tolerance in 95% pancreatectomized rats. Endocrinology. 152(7):2580–2588.
   PubMed Web of Science ®Google Scholar
• Terry, N. A., Walp, E. R., Lee, R. A., Kaestner, K. H. and May, C. L. (2014). Impaired enteroendocrine development in intestinal-specific Islet1 mouse mutants causes impaired glucose homeostasis. Am. J. Physiol. Gastrointest. Liver Physiol. 307(10):G979–G991.
   PubMed Web of Science ®Google Scholar
• Toft-Nielsen, M. B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K. and Holst, J. J. (2001). Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 86(8):3717–3723.
   PubMed Web of Science ®Google Scholar
• Tong, J., Prigeon, R. L., Davis, H. W., Bidlingmaier, M., Kahn, S. E., Cummings, D. E. and D'Alessio, D. (2010). Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 59(9):2145–2151.
   PubMed Web of Science ®Google Scholar
• Trimble, E. R., Gerber, P. P. and Renold, A. E. (1981). Abnormalities of pancreatic somatostatin secretion corrected by in vivo insulin treatment of streptozotocin-diabetic rats. Diabetes. 30(10):865–867.
   PubMed Web of Science ®Google Scholar
• Turnbaugh, P. J, Ridaura, V. K., Faith, J. J., Rey, F. E., Knight, R. and Gordon, J. I. (2009). The effect of diet on the human gut microbiome: A metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med. 1(6):6–14.
   Web of Science ®Google Scholar
• Turnbaugh, P. J., B¨ ackhed, F., Fulton, L. and Gordon, J. I. (2008). Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host. Microbe. 3:213–223.
   PubMed Web of Science ®Google Scholar
• Ueno, H., Shiiya, T., Mizuta, M., Mondal, S. M. and Nakazato, M. (2007). Plasma ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics. Endocr. J. 54(6):895–902.
   PubMed Web of Science ®Google Scholar
• Ueno, N., Inui, A., Asakawa, A., Takao, F., Komatsu, Y., Kotani, K. and Kasuga, M. (2002). Mosapride, a 5HT-4 receptor agonist, improves insulin sensitivity and glycaemic control in patients with Type II diabetes mellitus. Diabetologia. 45(6):792–797.
   PubMed Web of Science ®Google Scholar
• Ukkola, O. H., Puurunen, V. P., Piira, O. P., Niva, J. T., Lepojärvi, E. S., Tulppo, M. P. and Huikuri, H. V. (2011). High serum fasting peptide YY (3–36) is associated with obesity-associated insulin resistance and type 2 diabetes. Regul. Pept. 170(1–3):38–42.
   PubMedGoogle Scholar
• Urbano, F., Filippello, A., Di Pino, A., Barbagallo, D., Di Mauro, S., Pappalardo, A. and Piro, S. (2016). Altered expression of uncoupling protein 2 in GLP-1-producing cells after chronic high glucose exposure: Implications for the pathogenesis of diabetes mellitus. Am. J. Physiol. Cell Physiol. 310(7):C558–C567.
   PubMed Web of Science ®Google Scholar
• Utzschneider, K. M., Kratz, M., Damman, C. J. and Hullarg, M. (2016).Mechanisms linking the gut microbiome and glucose metabolism. J. Clin. Endocrinol. Metab. 101(4):1445–1454.
   PubMed Web of Science ®Google Scholar
• Vamvini, M. T., Hamnvik, O.-P., Sahin-Efe, A., Gavrieli, A., Dincer, F., Farr, O. M. and Mantzoros, C. S. (2016). Differential effects of oral and intravenous lipid administration on key molecules related to energy homeostasis. J. Clin. Endocrinol. Metab. 101(5):1989–1997.
   PubMed Web of Science ®Google Scholar
• Vella, A. (2013). Enteroendocrine secretion after Roux-en-Y gastric bypass: Is it important? Neurogastroenterology and motility. Off. J. Eur. Gastrointestinal Motil. Soc. 25(1):1–3.
   PubMed Web of Science ®Google Scholar
• Vilsboll, T., Krarup, T., Deacon, C. F., Madsbad, S. and Holst, J. J. (2001). Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 50(3):609–613.
   PubMed Web of Science ®Google Scholar
• Vilsboll, T., Krarup, T., Madsbad, S. and Holst, J.J. (2002). Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 45:1111–1119.
   PubMed Web of Science ®Google Scholar
• Vincent, R. P., Omar, S., Ghozlan, S., Taylor, D. R., Cross, G., Sherwood, R. A., Fandriks, L., Olbers, T., Werling, M., Alaghband-Zadeh, J., le Roux, C. W.(2013). Higher circulating bile acid concentrations in obese patients with type 2 diabetes. Ann. Clin. Biochem. 50(Pt 4):360–364.
   PubMed Web of Science ®Google Scholar
• Vrieze, A., Van Nood, E., Holleman, F., Salojarvi, J., Kootte, R. S., Bartelsman, J. F., et al. (2012). Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 143(4):913–916.e7.
   PubMed Web of Science ®Google Scholar
• Ward, F. R., Leblanc, H. and Yen, S. S. (1977). The inhibitory effect of somatostatin on growth hormone, insulin and glucagon secretion in diabetes mellitus. J. Clin. Endocrinol Metab. 41(3):527–532.
   Web of Science ®Google Scholar
• Weintraub, M., Sundaresan, P. R., Madan, M., Schuster, B., Balder, A., Lasagna, L. and Cox, C. (1992). Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin. Pharmacol. Ther. 51(5):586–594.
   PubMed Web of Science ®Google Scholar
• Weltzin, T. E., Fernstrom, M. H., Fernstrom, J. D., Neuberger, S. K. and Kaye, W. H. (1995). Acute tryptophan depletion and increased food intake and irritability in bulimia nervosa. Am. J. Psychiatry. 152(11):1668–1671.
   PubMed Web of Science ®Google Scholar
• Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J. and Holst, J. J.(1993). Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 38(4):665–673.
   PubMed Web of Science ®Google Scholar
• Widenmaier, S. B., Kim, S.-J., Yang, G. K., De Los Reyes, T., Nian, C., Asadi, A. and McIntosh, C. H. S. (2010). A GIP receptor agonist exhibits β-cell anti-apoptotic actions in rat models of diabetes resulting in improved β-cell function and glycemic control. Plos One. 5(3):e9590.
   PubMed Web of Science ®Google Scholar
• Williams, D. L., Hyvarinen, N., Lilly, N., Kay, K., Dossat, A., Parise, E. and Torregrossa, A.M. (2011). Maintenance on a high-fat diet impairs the anorexic response to glucagon-like-peptide-1 receptor activation. Physiology Behavior. 103(5):557–564.
   PubMed Web of Science ®Google Scholar
• Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W. and Nauck, M. A. (1996). Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 81(1):327–332.
   PubMed Web of Science ®Google Scholar
• Wozniak, K. M. 1., Linnoila, M. (1991). Hyperglycemic properties of serotonin receptor antagonists. Life Sci. 49(2):101–109.
   PubMed Web of Science ®Google Scholar
• Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A. and Bloom, S. R. (2001). Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol Metab. 86(12):5992.
   PubMed Web of Science ®Google Scholar
• Wright, M., Woodrow, G., O'Brien, S., Armstrong, E., King, N., Dye, L., Blundell, J., Brownjohn, A. and Turney, J. (2004). Cholecystokinin and leptin: Their influence upon the eating behaviour and nutrient intake of dialysis patients. Nephrol. Dial. Transplant. 19(1):133–140.
   PubMed Web of Science ®Google Scholar
• Yabe, D. and Seino, Y. (2011). Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and β cell preservation. Progress Biophys. Mol. Biol. 107(2):248–256.
   PubMed Web of Science ®Google Scholar
• Yakovlieva, M., Tacheva, T., Mihaylova, S., Tropcheva, R., Trifonova, K., Toleкova, A., Danova, S. and Vlaykova, T. (2015). Influence of Lactobacillus brevis 15 and Lactobacillus plantarum 13 on blood glucose and body weight in rats after high-fructose diet. Benef. Microbes. 6(4):505–512.
   PubMed Web of Science ®Google Scholar
• Zhang, S., Wang, S., Hyrc, K. and Wice, B. M. (2013). Metabolic profiling identifies beta-hydroxypyruvate (HP) as a potential mediator of type 2 diabetes mellitus (T2DM) in mice. Diabetes. 62: A524.
   Web of Science ®Google Scholar
• Zhang, S., Wang, S., Puhl, M. D., Jiang, X., Hyrc, K. L., Laciny, E., Wallendorf, M. J., Pappan, K. L., Coyle, J. T. and Wice, B. M. (2015). Global biochemical profiling identifies β-hydroxypyruvate as a potential mediator of type 2 diabetes in mice and humans. Diabetes. 64:1383–1394.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Ying, B., Shi, L., Fan, H., Yang, D., Xu, D. and Wen, F. (2007). Ghrelin inhibit cell apoptosis in pancreatic beta cell line HIT-T15 via mitogen-activated protein kinase/phosphoinositide 3-kinase pathways. Toxicology. 237(1–3):194–202.
   PubMed Web of Science ®Google Scholar